Content provided in partnership with

The first U.S. human gene therapy trial targeting Duchenne Muscular Dystrophy , launched in March at Columbus Children's Hospital in Ohio, will move to a second stage with $2.5 million grant from the Muscular Dystrophy Association and matching funds from Asklepios BioPharmaceutical of Chapel Hill

The first U.S. human gene therapy trial targeting Duchenne Muscular Dystrophy (DMD), launched in March at Columbus Children's Hospital in Ohio, will move to a second stage with $2.5 million grant from the Muscular Dystrophy Association (MDA) and matching funds from Asklepios BioPharmaceutical (AskBio) of Chapel Hill.

Most Popular Articles in Technology: An overview of continuous data protection; Why all those current ratings?; Many countries now have a mobile penetration rate above 100%, report says; The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...; MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...; More »

AskBio will conduct further large animal studies in canine and non-human primate DMD models to test the safety and effectiveness of systemic delivery of Biostrophin, its lead gene therapy candidate for DMD.

Technology Industry

The first U.S. human gene therapy trial targeting Duchenne Muscular Dystrophy , launched in March at Columbus Children's Hospital in Ohio, will move to a second stage with $2.5 million grant from the Muscular Dystrophy Association and matching funds from Asklepios BioPharmaceutical of Chapel Hill

BT Catalyst, Jan-Feb, 2007

Find Research Guides for:

Find Featured Titles for: News

Most Popular Articles in Technology

Most Popular Publications in Technology